These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 22067401

  • 21. B-Raf Inhibition in the Clinic: Present and Future.
    Fiskus W, Mitsiades N.
    Annu Rev Med; 2016; 67():29-43. PubMed ID: 26768236
    [Abstract] [Full Text] [Related]

  • 22. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.
    N Engl J Med; 2015 Jan 01; 372(1):30-9. PubMed ID: 25399551
    [Abstract] [Full Text] [Related]

  • 23. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
    Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L.
    J Clin Oncol; 2015 Dec 01; 33(34):4032-8. PubMed ID: 26460303
    [Abstract] [Full Text] [Related]

  • 24. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.
    Cohen DN, Lawson SK, Shaver AC, Du L, Nguyen HP, He Q, Johnson DB, Lumbang WA, Moody BR, Prescott JL, Chandra PK, Boyd AS, Zwerner JP, Robbins JB, Tyring SK, Rady PL, Chappell JD, Shyr Y, Infante JR, Sosman JA.
    Clin Cancer Res; 2015 Jun 01; 21(11):2624-34. PubMed ID: 25724524
    [Abstract] [Full Text] [Related]

  • 25. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
    Schneider TC, Kapiteijn E, van Wezel T, Smit JWA, van der Hoeven JJM, Morreau H.
    BMC Cancer; 2016 Jan 19; 16():31. PubMed ID: 26786320
    [Abstract] [Full Text] [Related]

  • 26. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
    Smith KJ, Haley H, Hamza S, Skelton HG.
    Dermatol Surg; 2009 Nov 19; 35(11):1766-70. PubMed ID: 19660024
    [Abstract] [Full Text] [Related]

  • 27. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M.
    Ann Pathol; 2013 Dec 10; 33(6):375-85. PubMed ID: 24331719
    [Abstract] [Full Text] [Related]

  • 33. Paradoxical oncogenesis: are all BRAF inhibitors equal?
    Menzies AM, Kefford RF, Long GV.
    Pigment Cell Melanoma Res; 2013 Sep 10; 26(5):611-5. PubMed ID: 23795808
    [Abstract] [Full Text] [Related]

  • 34. Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.
    Picard A, Pedeutour F, Peyrade F, Saudes L, Duranton-Tanneur V, Chamorey E, Cardot-Leccia N, Sudaka A, Ettaiche M, Benchetrit M, Poissonnet G, Weinbreck N, Dadone B, Lacour JP, Passeron T, Montaudié H.
    JAMA Dermatol; 2017 Apr 01; 153(4):291-298. PubMed ID: 28259104
    [Abstract] [Full Text] [Related]

  • 35. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
    Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R.
    Arch Dermatol; 2008 Jun 01; 144(6):779-82. PubMed ID: 18559769
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM.
    BioDrugs; 2012 Oct 01; 26(5):325-34. PubMed ID: 22946753
    [Abstract] [Full Text] [Related]

  • 38. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 01; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.